Literature DB >> 1346236

Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines.

B L King1, D Carter, H G Foellmer, B M Kacinski.   

Abstract

In this communication, the authors summarize their characterization of eight ovarian adenocarcinoma-derived cell lines for level of neu gene amplification, expression of neu transcripts and protein, and intraperitoneal tumorigenicity in nude mice. Two of the eight cell lines in our study (SKOV3 and YAOVBIX1) exhibited five- to ninefold neu DNA sequence amplification, accompanied by up to 200-fold overexpression of transcripts and protein (p185). Both of these cell lines expressed a major approximately 7.5 kb neu-complementary transcript not previously reported in other neu-positive tumor cell lines. One pair of cell lines (YAOVBIX1 and YAOVBIX3), isolated from a single ovarian carcinoma patient's ascites sample differed dramatically in regard to level of neu gene amplification and expression. Immunohistochemical staining of the primary ovarian tumor from which these two lines were derived demonstrated populations of both neu-positive and neu-negative malignant epithelial cells. Seven of the eight ovarian carcinoma lines produced intra-abdominal tumors after intraperitoneal injection into nude mice, irrespective of level of neu gene expression. This study demonstrates tumor cell heterogeneity with regard to neu gene amplification and expression in an ovarian adenocarcinoma, reveals the overexpression of novel neu-complementary transcripts in two independently isolated ovarian adenocarcinoma cell lines, and suggests that neu gene expression is not required for intraperitoneal tumorigenicity of ovarian carcinoma xenografts in a nude mouse model system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346236      PMCID: PMC1886242     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

Review 2.  The nude mouse in cancer research.

Authors:  B C Giovanella; J Fogh
Journal:  Adv Cancer Res       Date:  1985       Impact factor: 6.242

3.  Stage- and tissue-specific expression of the neu oncogene in rat development.

Authors:  Y Kokai; J A Cohen; J A Drebin; M I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

4.  Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2.

Authors:  R Lupu; R Colomer; G Zugmaier; J Sarup; M Shepard; D Slamon; M E Lippman
Journal:  Science       Date:  1990-09-28       Impact factor: 47.728

5.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors:  A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

6.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

Authors:  C R King; M H Kraus; S A Aaronson
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

7.  p185neu expression in human lung adenocarcinomas predicts shortened survival.

Authors:  J A Kern; D A Schwartz; J E Nordberg; D B Weiner; M I Greene; L Torney; R A Robinson
Journal:  Cancer Res       Date:  1990-08-15       Impact factor: 12.701

8.  Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts.

Authors:  C Shih; L C Padhy; M Murray; R A Weinberg
Journal:  Nature       Date:  1981-03-19       Impact factor: 49.962

9.  Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. A bi-institutional study of 47 cases.

Authors:  C N Otis; D Carter; S Cole; H Battifora
Journal:  Am J Surg Pathol       Date:  1987-06       Impact factor: 6.394

10.  Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells.

Authors:  R Zakut-Houri; B Bienz-Tadmor; D Givol; M Oren
Journal:  EMBO J       Date:  1985-05       Impact factor: 11.598

View more
  13 in total

1.  Mammalian Ste20-like kinase (Mst2) indirectly supports Raf-1/ERK pathway activity via maintenance of protein phosphatase-2A catalytic subunit levels and consequent suppression of inhibitory Raf-1 phosphorylation.

Authors:  Geoffrey K Kilili; John M Kyriakis
Journal:  J Biol Chem       Date:  2010-03-08       Impact factor: 5.157

2.  A polymerase chain reaction-based microsatellite typing assay used for tumor cell line identification.

Authors:  B L King; A Lichtenstein; J Berenson; B M Kacinski
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

3.  HER2/NEU GENE EXPRESSION PRODUCTS EVALUATED WITH SUPERPARAMAGNETIC, GENETICALLY ENGINEERED ANTIBODIES.

Authors:  Marek Malecki
Journal:  Proc S Dak Acad Sci       Date:  2007

4.  Signaling of ERBB receptor tyrosine kinases promotes neuroblastoma growth in vitro and in vivo.

Authors:  Kristen N Richards; Patrick A Zweidler-McKay; Nadine Van Roy; Frank Speleman; Jesus Trevino; Peter E Zage; Dennis P M Hughes
Journal:  Cancer       Date:  2010-07-01       Impact factor: 6.860

Review 5.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

6.  OVARIAN CANCER SUICIDE GENE THERAPY WITH GENETICALLY ENGINEERED, TRANSGENICALLY EXPRESSED, INTRACELLULAR scFv ANTIBODIES AGAINST ANTI-OXIDATIVE ENZYMES.

Authors:  Marek Malecki; Raf Malecki
Journal:  Proc S Dak Acad Sci       Date:  2008

7.  Targeted covalent inactivation of protein kinases by resorcylic acid lactone polyketides.

Authors:  Andreas Schirmer; Jonathan Kennedy; Sumati Murli; Ralph Reid; Daniel V Santi
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

8.  Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas.

Authors:  D L Persons; L C Hartmann; J F Herath; T J Borell; W A Cliby; G L Keeney; R B Jenkins
Journal:  Am J Pathol       Date:  1993-03       Impact factor: 4.307

9.  Her-2 DNA versus cell vaccine: immunogenicity and anti-tumor activity.

Authors:  Paula J Whittington; Olga Radkevich-Brown; Jennifer B Jacob; Richard F Jones; Amy M Weise; Wei-Zen Wei
Journal:  Cancer Immunol Immunother       Date:  2008-10-03       Impact factor: 6.968

10.  Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice.

Authors:  Olga Radkevich-Brown; Jennifer Jacob; Michael Kershaw; Wei-Zen Wei
Journal:  Cancer Res       Date:  2009-01-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.